Anatara Lifesciences (ASX:ANR), a developer of evidence based solutions for gastrointestinal diseases in humans and animals is pleased to provide this update on clinical trial activities.
Anatara Lifesciences Ltd (ASX:ANR) Q3 FY21 Activities Report
Q3 FY21 Activities ReportMelbourne, April 27, 2021 AEST (ABN Newswire) - Anatara Lifesciences (
ASX:ANR), a developer of non-antibiotic oral solutions for gastrointestinal diseases in animals and humans, is pleased to provide this activities report for the quarter ending 31 March 2021, along with the Company s Appendix 4C cash flow report.
Commenting on the quarter, CEO Steve Lydeamore said, Anatara is pleased to have successfully progressed two key milestones during the period - a successful trial for Anatara s proprietary enriched formulation for poultry in water, and ethics approval to start the human IBS trial. Anatara now has approval to commence two separate human trials for its Gastrointestinal Re-Programming complementary medicine (GaRP), and there appears to be a wider appreciation of the Company s human health initiatives and the potential to improve overall human wellbeing with a market different
Anatara Lifesciences Ltd (ASX:ANR) Ethics Approve Adult Psychological Functioning Trial start abnnewswire.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from abnnewswire.net Daily Mail and Mail on Sunday newspapers.
Anatara Lifesciences Ltd (ASX:ANR) Announces Australian Patent Grant for Detach
Announces Australian Patent Grant for DetachMelbourne, April 16, 2021 AEST (ABN Newswire) - Anatara Lifesciences Ltd (
ASX:ANR) is pleased to announce the grant of patent number AU2019204496 entitled Anti-diarrhea formulation which avoids antimicrobial resistance .
- Granting of patent number AU2019204496 strengthens Anatara s intellectual property position (IP) in the treatment and prevention of diarrhea caused by pathogenic microbes
- The patent provides the pathway for Anatara to further pursue commercialisation opportunities for Detach(R)
- Patent expires on 24 August 2038
- Piglet challenge study commenced
Anatara s animal heath product, Detach(R), uses the patent as a non-antibiotic approach to aid in the control of diarrheal disease (known as scour), developed using bromelain, an extract from pineapple stems.
Anatara Lifesciences Ltd (ASX:ANR) Market Update
Market UpdateMelbourne, April 7, 2021 AEST (ABN Newswire) - Anatara Lifesciences Ltd (
ASX:ANR) provides an update on development and commercialisation activities for human health and animal health projects.
Anatara is pleased that activities for the March quarter progressed favourably and near to anticipated timelines. There appears to be a wider appreciation of Anatara s human health initiatives with a focus on using the restoration and/or maintenance of gastrointestinal tract harmony to improve overall wellbeing and with a market differentiating focus on evidence based complementary medicine.
Anatara has ethics approval to commence the human clinical trial in irritable bowel syndrome (IBS) with Anatara s Gastrointestinal ReProgramming (GaRP) complementary medicine. Due to a scheduling delay in manufacturing placebo for this trial as a result of reduced shifts under covid restrictions, the Company now anticipates comme